Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.
about
Monitoring minimal residual disease in acute myeloid leukaemia: a review of the current evolving strategiesAdvancing the Minimal Residual Disease Concept in Acute Myeloid LeukemiaMeasurable residual disease testing in acute myeloid leukaemia.Evaluation of BM cytomorphology after allo-SCT in patients with AML.Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.Minimal residual disease in acute myeloid leukaemiaCore-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia.Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.Molecular diagnosis of acute myeloid leukemia.Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation.Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation.Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age.Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors.Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.B-cell identity as a metabolic barrier against malignant transformation.The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients.BAALC expression: a suitable marker for prognostic risk stratification and detection of residual disease in cytogenetically normal acute myeloid leukemia.Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.Molecular and alternative methods for diagnosis of acute myeloid leukemia with mutated NPM1: flexibility may help.A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone.High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients.Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease.Value of routine bone marrow examination in pediatric acute myeloid leukemia (AML): a study of the Dutch Childhood Oncology Group (DCOG).Longitudinal qPCR monitoring of nucleophosmin 1 mutations after allogeneic hematopoietic stem cell transplantation to predict AML relapse.NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression.Clinical significance of quantitative monitoring and mutational analysis of BCR-ABL1 transcript in Philadelphia chromosome positive B lymphoblastic leukemia.Targeted next-generation sequencing detects point mutations, insertions, deletions and balanced chromosomal rearrangements as well as identifies novel leukemia-specific fusion genes in a single procedureRelapse kinetics in acute myeloid leukaemias withMLLtranslocations or partial tandem duplications within theMLLgene
P2860
Q26770394-3FDD977F-A325-446E-B326-6AA3851CDB43Q28087291-1BF7AD9A-E4A4-41AA-BF94-F7A6815482BDQ30234914-3E7B1CFC-656F-4F9C-9715-7BDF26FBB8B3Q30318110-2E4DDE79-BFA2-42A2-940A-5A881973697AQ33832709-9662C14D-7751-44B7-8C7D-F7D54DC0EF47Q33978907-C4C757D3-37F5-4368-8642-4A293622B830Q34086334-D0673A40-BC43-44DE-9C53-1B7855622A30Q34179265-AABF0568-92AB-4353-9FC8-62E2E481CC17Q34663691-78D69141-AC7D-4D8D-BDDA-B89C5FFBD7D7Q35971837-B30BEBAF-2E71-4186-BF20-6E0387F87F7DQ36053792-91BB2C07-A550-4119-8F33-63C2615A4BD0Q36750458-B4140911-8E3A-4CA2-83BB-CE76CF6A4CF5Q37809866-A1D29C9C-E377-47D6-912F-466BBC51D873Q38022075-53BCE64F-AC55-41B3-A0B1-E47D9776266BQ38105123-C3FCF68B-7C19-4E37-A750-1DF3714E58C9Q38240563-B2435CFF-98B2-460A-B600-258B9B621FCBQ38263126-AD7BF79D-6ADF-444C-ADBA-9670A7E65F7CQ39132424-D3DE1E46-705A-4602-8CCC-F91163ECB997Q39285841-85E37F44-DB7E-4AE1-8D25-2A2525A35045Q39401267-AF08DE10-0D6A-408F-A85B-4FE399B5AFF2Q41553306-06E3E8C2-59B2-4B80-B82C-8C1FFF10D68BQ41885481-EA1A8258-3C9C-4C20-820B-DAEE1F452620Q41973082-A57411DD-AE59-40B8-9AD8-F9B59A634951Q42832529-05299303-5AA3-4FED-8053-8AA119F12047Q43120262-9517377E-3C0E-4EDB-A3C0-475F62F6E3BEQ47156797-CCCD60CE-9CE0-4469-9C45-3DA847F6A4CBQ47745405-B6EC9205-C8CD-42A0-9B00-B194A85E82ACQ50142472-09628EEE-D5BD-4F36-A5A9-9196B9B331DAQ53257785-FF9717BE-33CB-4DB6-BCB6-7C03A0C412A3Q54362611-96E7E438-D57D-4FEC-B3FB-E7635396C638Q55068793-1661C96F-EA54-4264-9E34-4ABC33A6494DQ57740688-78A5D4F8-C681-492E-A7E1-6FEFA8A0E6BBQ59194210-F23E6131-73A4-41DF-BDC3-C55E241DD9A5
P2860
Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Strikingly different molecular ...... MYH11 acute myeloid leukemias.
@en
Strikingly different molecular ...... MYH11 acute myeloid leukemias.
@nl
type
label
Strikingly different molecular ...... MYH11 acute myeloid leukemias.
@en
Strikingly different molecular ...... MYH11 acute myeloid leukemias.
@nl
prefLabel
Strikingly different molecular ...... MYH11 acute myeloid leukemias.
@en
Strikingly different molecular ...... MYH11 acute myeloid leukemias.
@nl
P2093
P50
P1433
P1476
Strikingly different molecular ...... MYH11 acute myeloid leukemias.
@en
P2093
David Grimwade
Ingrid Beier Ommen
Jelena V Jovanovic
Mette Østergaard
P304
P356
10.1182/BLOOD-2009-04-212530
P407
P577
2009-11-09T00:00:00Z